miR-22-5p revealed as a potential biomarker involved in the acute phase of myocardial infarction via profiling of circulating microRNAs

Maciejak, Agata; Kiliszek, Marek; Opolski, Grzegorz; Segiet, Agnieszka; Matlak, K.; Dobrzycki, Sławomir; Tulacz, Dorota; Sygitowicz, Grażyna; Burzyńska, Beata; Góra, Monika

doi:10.3892/mmr.2016.5566

Cited by 31 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plasma and serum samples were stored at −80 °C until analysis. Assessment of hemolysis in the samples was performed as described previously 39 .…”

Section: Methodsmentioning

confidence: 99%

Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction

Maciejak

Kostarska-Srokosz

Gierlak

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

Left ventricular (LV) dysfunction after acute myocardial infarction (AMI) is associated with an increased risk of heart failure (HF) development. Diverse microRNAs (miRNAs) have been shown to appear in the bloodstream following various cardiovascular events. The aim of this study was to identify prognostic miRNAs associated with LV dysfunction following AMI. Patients were divided into subgroups comprising patients who developed or not LV dysfunction within six months of the infarction. miRNA profiles were determined in plasma and serum samples of the patients on the first day of AMI. Levels of 14 plasma miRNAs and 16 serum miRNAs were significantly different in samples from AMI patients who later developed LV dysfunction compared to those who did not. Two miRNAs were up-regulated in both types of material. Validation in an independent group of patients, using droplet digital PCR (ddPCR) confirmed that miR-30a-5p was significantly elevated on admission in those patients who developed LV dysfunction and HF symptoms six months after AMI. A bioinformatics analysis indicated that miR-30a-5p may regulate genes involved in cardiovascular pathogenesis. This study demonstrates, for the first time, a prognostic value of circulating miR-30a-5p and its association with LV dysfunction and symptoms of HF after AMI.

show abstract

“…The plasma and serum samples were stored at −80 °C until analysis. Assessment of hemolysis in the samples was performed as described previously 39 .…”

Section: Methodsmentioning

confidence: 99%

Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction

Maciejak

Kostarska-Srokosz

Gierlak

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, the nuclease-resistant extracellular miRNAs have been found that they are present in human blood plasma [9, 10], and displayed some characteristics of an ideal biomarker. There are a mounting number of reports identifying specific plasma miRNAs as potential biomarkers including cancer [11], heart failure [12], myocardial infarction [13] and so on. However, few studies have explored plasma miRNAs expression difference in KD patients.…”

Section: Introductionmentioning

confidence: 99%

A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs

Jiang

Tian

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundKawasaki disease (KD) is a childhood systemic vasculitis that exhibits a specific preference for the coronary arteries. The aetiology remains unknown and there are no especially diagnostic tests. microRNAs (miRNAs) are 18 to 23 nucleotides non-coding RNAs that are negative regulator of gene expression and play a crucial role in the regulatory network of the genome. Recently, circulating miRNAs have been found presentation in human plasma and displayed some characteristics of the ideal biomarker. However, few researches explored differentially expressed miRNAs in the plasma of KD patients. Our study is to identify circulating miRNAs in KD plasma which can serve as potential biomarkers of KD diagnosis.Materials and methodsThe total of five pairs of acute KD and normal plasma samples were analyzed using ABI miRNAs TLDA Assay chip. Differentially expression of miR-125a-5p in plasma were confirmed by quantitative real-time PCR (qRT-PCR) in independent cohort (acute KD = 30, convalescent KD = 30 and healthy control = 32). After bioinformatics prediction, miR-125a-5p vector and inhibitor were transfected into HUVECs respectively, to observe MKK7 expression as a potential target gene. Flow cytometry was used to analyze apoptosis. The mRNA and protein levels of desired genes including MKK7, Caspase-3, Bax and Bcl2 were detected by qRT-PCR and western blotting.ResultsEighteen miRNAs were differentially expressed in acute KD’s plasma compared with healthy control. miR-125a-5p was significantly increased in plasma of KD patients (p = 0.000), but no variation between acute and convalescent KD (p = 0.357). Moreover, the results from the gain and loss functions of miR-125a-5p in HUVECs have shown that miR-125a-5p remarkably suppressed MKK7 expression, as a novel target gene. Importantly, miR-125a-5p also induced apoptosis in HUVECs through inhibition MKK7 levels to regulate Bax/Bcl2 pathway resulting to activate Caspase-3.ConclusionOur study indicated that the circulating miR-125a-5p levels in KD’s plasma have remarkably evaluated compared with healthy individuals. miR-125a-5p might play a role in the development of KD by regulating target gene MKK7 to induce apoptosis in vascular endothelial cells. Therefore, our findings have suggested that detected miR-125a-5p levels in plasma could be used as a potential biomarker in early KD diagnosis.

show abstract

“…However, the expression level of circulating miR-134-5p in patients with ACS or early AMI was significantly increased [37,52]. The expression of miR-22-5p in plasma of patients with AMI was significantly decreased [76], but the expression of miR-22-5p in serum was significantly increased [77]. The expression of circulating miR-423-5p was downregulated within 24 hours in AMI patients [78], but increased within 6 hours in STEMI, unstable angina, and even AMI patients [26,56,79].…”

Section: Resultsmentioning

confidence: 94%

Noncoding RNAs as Biomarkers for Acute Coronary Syndrome

Wang

Jin

2020

BioMed Research International

View full text Add to dashboard Cite

Acute coronary syndrome (ACS), consisting of acute myocardial infarction and unstable angina, is the most dangerous and fatal form of coronary heart disease. Acute coronary syndrome has sudden onset and rapid development, which may lead to malignant life-threatening conditions at any time. Therefore, early detection and diagnosis are critical for patients with ACS. Recent studies have found that noncoding RNA is of great significance in the diagnosis and treatment of cardiovascular diseases. In this review, we summarized recent data on circulating noncoding RNAs (including microRNA, long noncoding RNA, and circular RNA) as diagnostic and prognostic markers in ACS including acute myocardial infarction and unstable angina. Specifically, microRNAs (miRNAs) as diagnostic markers are divided into three types: miRNAs of increased expression in ACS, miRNAs of decreased expression in ACS, and miRNAs of contradictory expression in ACS. Moreover, we described these miRNAs of increased expression in ACS based on miRNAs family. This review may result in a great guidance of noncoding RNAs as biomarkers for ACS in clinical practice.

show abstract

miR-22-5p revealed as a potential biomarker involved in the acute phase of myocardial infarction via profiling of circulating microRNAs

Cited by 31 publications

References 18 publications

Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction

Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction

A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs

Noncoding RNAs as Biomarkers for Acute Coronary Syndrome

Contact Info

Product

Resources

About